Clinically relevant concentrations of lidocaine inhibit tumor angiogenesis through suppressing VEGF/VEGFR2 signaling
ConclusionsThis study is the first to report that lidocaine acts as an angiogenesis inhibitor. The findings provide preclinical evidence into the potential mechanisms by which lidocaine may negatively affect cancer growth and metastasis.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Anesthesia | Anesthesiology | Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Lidoderm | Melanoma | Skin Cancer | Study